The RECoVaM study has just shown that the efficacy of the Sinovac vaccine rapidly drops after 2 months!

Here is what you need to know!

 

RECoVaM Identifies Sinovac Vaccine Efficacy Problem

When the Sinovac CoronaVac vaccine was introduced, it was already known that it was the least efficacious vaccine against symptomatic COVID-19.

However, it was heavily adopted in many countries because it was available, and it offered very good protection against hospitalisation and death.

However, the recent RECoVaM (Real-world Evaluation of Covid-19 Vaccines in Malaysia) study identified a problem with the efficacy of the Sinovac vaccine against hospitalisation and death.

The RECoVaM study was conducted from 1 April until 12 September 2021, during which over 14.5 million people in Malaysia were fully vaccinated, out of an estimated population of 32.7 million.

Let’s take a look at the results…

Note : I should point out that the AstraZeneca results in the RECoVaM study may be skewed because it was taken up by a younger part of the population.

ICU Admissions

Despite the Sinovac’s Phase 3 trials showing that it offered very good protection against ICU admissions, the RECoVaM study discovered that a comparably high number of Sinovac recipients ended up in the ICU.

The ICU breakthrough rate of 0.011% may seem very low, but that’s 1 out of 9,000 Sinovac recipients and 5.4x higher than the Pfizer vaccine.

Vaccine	ICU Breakthrough	vs Pfizer	vs AstraZeneca
Sinovac	0.011%	+5.4x	+144x
Pfizer	0.002%	Baseline	+21x
AstraZeneca	0.001%	-21x	Baseline

Deaths

The Sinovac vaccine was good at preventing deaths, but even so – 1 out of 6,700 Sinovac recipients died from COVID-19. The Pfizer vaccine, in comparison, was 3x better at preventing deaths.

Vaccine	Death Breakthrough	vs Pfizer	vs AstraZeneca
Sinovac	0.015%	+3.4x	+79x
Pfizer	0.005%	Baseline	+23x
AstraZeneca	0.002%	-23x	Baseline

 

Sinovac Vaccine Efficacy Rapidly Drops After 2 Months!

On 23 November 2021, JKJAV shared an analysis of the RECoVaM data, showing WHY the Sinovac CoronaVac vaccine was not performing as expected.

The RECoVaM data showed that there was a precipitous drop in Sinovac’s effectiveness against infection and ICU admission after the first two months of full protection.

The Sinovac vaccine’s protection against symptomatic COVID-19 infection dropped from 76% to just 28%, while its protection against ICU admission dropped from 55% to just 28%.

The good news is that it still offers good protection against death at 76%. However, that protection still pales against the protection offered by better vaccines like the Pfizer COMIRNATY vaccine.

When we are talking about millions of people getting vaccinated, every 1% in difference means tens of thousands of additional deaths.

That is why Malaysia is now offering a FREE Pfizer booster dose for Sinovac vaccine recipients, just three months after receiving Dose 2.

The Pfizer booster dose will give Sinovac vaccine recipients a much needed boost in protection, bringing it up to par with those who were fortunate enough to get vaccinated with two doses of Pfizer.

So please look out for your booster dose notification, and make sure you get it ASAP!

And I recommend that you get the Pfizer booster dose right now, instead of waiting for a third dose of the Sinovac vaccine.

Read more : Can You And Should You Get A Sinovac Booster Dose?

 

 

Recommended Reading

• Should Malaysia Stop Giving Booster Dose To Save Lives?
• COVID-19 Vaccine Standby List : How To Register?
• Moderna CEO Stéphane Bancel Arrested For Vaccine Fraud?
• Pfizer Secretly Added Tromethamine To COVID-19 Vaccine For Kids?
• Why COVID-19 Vaccine Expiry Dates Keep Getting Extended!
• Did KKM Deputy DG Dr. Chua Die From Pfizer Booster Dose?

Go Back To > Health + Science | Tech ARP

 

Support Tech ARP!

Please support us by visiting our sponsors, participating in the Tech ARP Forums, or donating to our fund. Thank you!